Alpha-Pet for Prostate Cancer: Preclinical Investigation Using 149Tb-Psma-617

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-54150-w
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Results From Extended Lymphadenectomies With [111In]PSMA-617 for Intraoperative Detection of PSMA-PET/CT-positive Nodal Metastatic Prostate Cancer

EJNMMI Research
Nuclear MedicineRadiologyImaging
2020English

225Ac-Psma-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Preclinical Efficacy of a PSMA-targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

PSMA PET Ligands in Prostate Cancer: A Game‐changer?

Trends in Urology & Men's Health
2019English

Immunohistochemical Validation of PSMA-expression Measured by 68 Ga-Psma PET/CT in Primary Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Preclinical Evaluation and Pilot Clinical Study of Al18F-Psma-BCH for Prostate Cancer Imaging

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

64Cu-Psma-617: A Novel PSMA-targeted Radio-Tracer for PET Imaging in Gastric Adenocarcinoma Xenografted Mice Model

Oncotarget
Oncology
2017English

Correction To: 225Ac-Psma-617 in Chemotherapy-Naive Patients With Advanced Prostate Cancer: A Pilot Study

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Translocator Protein PET Imaging in a Preclinical Prostate Cancer Model

Molecular Imaging and Biology
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy